Mumbai: India’s Health Secretary Rajesh Bhushan said on Tuesday that four more COVID-19 vaccines are in the national regulatory pipeline. These include vaccines developed by Zydus Cadilla, Sputnik-V of Russia, Biological E and Genova.
Zydus Cadilla completed Phase 2 clinical trials of its coronavirus vaccine in December of last year and was approved for Phase 3. Similarly, phase 2 clinical trials of Russia’s Sputnik-V COVID-19 vaccine are also awaited and phase 3 trials are being carried out by its Indian partner Dr Reddy’s Laboratories.
In the case of Biological E, phase 1 clinical trials of its vaccine began in December and Phase 2 is expected to begin in March. Genova’s RnA-based COVID-19 vaccine is currently in Phase I, with Phase 2 clinical trials expected to begin in March of this year.
American Pharma giant Pfizer’s coronavirus vaccine will cost Rs 2,800 for two doses, while Moderna’s will cost anywhere between Rs 2,300 to Rs 2,700 per dose. A vaccine developed by China has been priced at Rs 5,600 per dose, while another Chinese vaccine will be made available in India at Rs 1,200 per dose.
The COVID-19 vaccine developed by Sputnik-V, Russia, will cost Rs 734 per dose, while the one developed by Johnson & Johnson is also expected to be priced at Rs 734 per dose.
Health Secretary Rajesh Bhushan said that the Government of India is buying the COVID-19 vaccine covishield of Oxford University and AstraZeneca from Pune-based Serum Institute of India (SII) for Rs 200 per dose.
He said that Covaxin, a coronavirus vaccine from Hyderabad-based Bharat Biotech, is being purchased by the Indian government at a cost of Rs 206 per dose. The vaccine was developed in collaboration with the Indian Council of Medical Research (ICMR) and the Pune-based National Institute of Virology (NIV). The centre is purchasing 38 lakh doses of Covaxin and the remaining 12 lakh doses will be available for free.